Gastroenterology
Volume 139, Issue 2 , Pages 409-417 , August 2010

Effects of Lesogaberan on Reflux and Lower Esophageal Sphincter Function in Patients With Gastroesophageal Reflux Disease

  • Guy E. Boeckxstaens

      Affiliations

    • Academic Medical Centre, Amsterdam, The Netherlands
    • Department of Gastroenterology, University Hospital Leuven, Catholic University of Leuven, Leuven, Belgium
    • Corresponding Author InformationReprint requests Address requests for reprints to: Guy E. Boeckxstaens, MD, Department of Gastroenterology, University Hospital Leuven, Catholic University of Leuven, Herestraat 49, 3000 Leuven, Belgium. fax: (32) 16 33 02 38
    • ,
  • Hanneke Beaumont

      Affiliations

    • Academic Medical Centre, Amsterdam, The Netherlands
    • ,
  • Veerle Mertens

      Affiliations

    • Department of Gastroenterology, University Hospital Leuven, Catholic University of Leuven, Leuven, Belgium
    • ,
  • Hans Denison

      Affiliations

    • AstraZeneca R&D, Mölndal, Sweden
    • ,
  • Magnus Ruth

      Affiliations

    • AstraZeneca R&D, Mölndal, Sweden
    • ,
  • John Adler

      Affiliations

    • AstraZeneca R&D, Mölndal, Sweden
    • ,
  • Debra G. Silberg

      Affiliations

    • AstraZeneca R&D, Wilmington, Deleware
    • ,
  • Daniel Sifrim

      Affiliations

    • Department of Gastroenterology, University Hospital Leuven, Catholic University of Leuven, Leuven, Belgium
    • Barts and The London School of Medicine and Dentistry, Queen Mary's College, University of London, London, United Kingdom

Received 15 February 2010 ,Accepted 29 April 2010.

References 

  1. Dodds WJ, Dent J, Hogan WJ, et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med. 1982;307:1547–1552
  2. Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest. 1980;65:256–267
  3. Trudgill NJ, Riley SA. Transient lower esophageal sphincter relaxations are no more frequent in patients with gastroesophageal reflux disease than in asymptomatic volunteers. Am J Gastroenterol. 2001;96:2569–2574
  4. Sifrim D, Holloway R. Transient lower esophageal sphincter relaxations: how many or how harmful?. Am J Gastroenterol. 2001;96:2529–2532
  5. Mittal RK, Holloway RH, Penagini R, et al. Transient lower esophageal sphincter relaxation. Gastroenterology. 1995;109:601–610
  6. Kahrilas PJ. GERD pathogenesis, pathophysiology, and clinical manifestations. Cleve Clin J Med. 2003;70(Suppl 5):S4–S19
  7. Penagini R, Carmagnola S, Cantu P, et al. Mechanoreceptors of the proximal stomach: role in triggering transient lower esophageal sphincter relaxation. Gastroenterology. 2004;126:49–56
  8. Hirsch DP, Tytgat GN, Boeckxstaens GE. Transient lower oesophageal sphincter relaxations—a pharmacological target for gastro-oesophageal reflux disease?. Aliment Pharmacol Ther. 2002;16:17–26
  9. Blackshaw LA. Receptors and transmission in the brain-gut axis: potential for novel therapies (IV. GABA(B) receptors in the brain-gastroesophageal axis). Am J Physiol Gastrointest Liver Physiol. 2001;281:G311–G315
  10. van Herwaarden MA, Samsom M, Rydholm H, et al. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther. 2002;16:1655–1662
  11. Zhang Q, Lehmann A, Rigda R, et al. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut. 2002;50:19–24
  12. Cange L, Johnsson E, Rydholm H, et al. Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease. Aliment Pharmacol Ther. 2002;16:869–873
  13. Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABAB agonist baclofen on 24-hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut. 2003;52:464–470
  14. Alstermark C, Amin K, Dinn SR, et al. Synthesis and pharmacological evaluation of novel γ-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors. J Med Chem. 2008;51:4315–4320
  15. Brändén L, Carlsson A, Jensen J, et al. The novel GABA(B) receptor agonist AZD3355 inhibits acid reflux and reduces esophageal acid exposure as measured by 24-hour pH metry in dogs (abstract). Gastroenterology. 2008;134(4 Suppl 1):A715
  16. Lehmann A, Brändén L, Carlsson A, et al. AZD3355, a novel GABA(B) receptor agonist, inhibits transient lower esophageal sphincter relaxations in the dog. Gastroenterology. 2008;134(4 Suppl 1):A49
  17. Boeckxstaens GE, Rydholm H, Adler J, et al. Effect of AZD3355, a novel GABA(B) receptor agonist, on transient lower esophageal sphincter relaxations in healthy subjects. Gastroenterology. 2009;136(Suppl 1):772
  18. Shaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol. 2001;96:52–57
  19. Revicki DA, Wood M, Wiklund I, et al. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res. 1998;7:75–83
  20. Holloway RH, Penagini R, Ireland AC. Criteria for objective definition of transient lower esophageal sphincter relaxation. Am J Physiol. 1995;268:G128–G133
  21. Sifrim D, Castell D, Dent J, et al. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut. 2004;53:1024–1031
  22. Lehmann A. Novel treatments of GERD: focus on the lower esophageal sphincter. Eur Rev Med Pharmacol Sci. 2008;12:103–110
  23. Young RL, Cooper NJ, Blackshaw LA. Anatomy of vagal afferent innervation of the crural diaphragm. Gastroenterology. 2008;134(4 Suppl 1):A74
  24. Vela MF, Tutuian R, Katz PO, et al. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther. 2003;17:243–251
  25. Sifrim D, Holloway R, Silny J, et al. Composition of the postprandial refluxate in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2001;96:647–655
  26. Del Tacca M, Blandizzi C, Bernardini MC. Central GABAA excitatory and GABAB inhibitory receptors regulate gastric acid secretion in rats. Eur J Pharmacol. 1990;177:189–194
  27. Blandizzi C, Bernardini MC, Natale G, et al. Phaclofen-sensitive GABA-B receptors do not mediate excitatory effects of baclofen on gastric secretion. Pharmacology. 1991;42:128–134
  28. Tutuian R, Vela MF, Hill EG, et al. Characteristics of symptomatic reflux episodes on acid suppressive therapy. Am J Gastroenterol. 2008;103:1090–1096
  29. Zerbib F, Duriez A, Roman S, et al. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut. 2008;57:156–160
  30. Bredenoord AJ, Weusten BL, Curvers WL, et al. Determinants of perception of heartburn and regurgitation. Gut. 2006;55:313–318
  31. Boeckxstaens GE, Beaumont H, Hatlebakk JG, et al. Efficacy and tolerability of the novel reflux inhibitor, AZD3355, as add-on treatment in GERD patients with symptoms despite proton pump inhibitor therapy. Gastroenterology. 2009;136(Suppl 1):M1875
  32. Mogyoros I, Bostock H, Burke D. Mechanisms of paresthesias arising from healthy axons. Muscle Nerve. 2000;23:310–320
  33. Brown DA, Adams PR, Higgins AJ, et al. Distribution of GABA-receptors and GABA-carriers in the mammalian nervous system. J Physiol (Paris). 1979;75:667–671
  34. Donnellan C, Sharma N, Preston C, et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2005;4:CD003245
  35. van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2004;CD002095
  36. Armstrong D, Pare P, Pericak D, et al. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol. 2001;96:2849–2857
  37. Hatlebakk JG, Hyggen A, Madsen PH, et al. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ. 1999;319:550–553
  38. Meineche-Schmidt V, Hauschildt Juhl H, Ostergaard JE, et al. Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care. Aliment Pharmacol Ther. 2004;19:907–915
  39. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58:295–309

 This article has an accompanying continuing medical education activity on page e16. Learning Objective: Upon completion of this exercise, successful learners will be able to describe key aspects of the mechanisms underlying gastroesophageal reflux disease and its treatment.

 Conflicts of interest The authors disclose the following: Dr Boeckxstaens has received an unrestricted grant, has participated in advisory boards of, and is/has been a consultant for AstraZeneca. Drs Denison, Ruth, Adler, and Silberg are employees of AstraZeneca. Dr Sifrim has received grant/research support from AstraZeneca. The remaining authors have no conflicts to disclose.

 Funding Supported by AstraZeneca R&D Mölndal, Sweden.

PII: S0016-5085(10)00659-1

doi: 10.1053/j.gastro.2010.04.051

Gastroenterology
Volume 139, Issue 2 , Pages 409-417 , August 2010

Article Tools

* Image Usage & Resolution